- Active not recruitingPHASE2, PHASE3
Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy
This study looks at new drug combinations for advanced non-small cell lung cancer that has progressed after standard treatments. It compares adding new medicines, cobolimab and dostarlimab, to docetaxel chemotherapy, to see if they work better together.
For: Lung Cancer, Non-Small CellUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
For: Only patients with oncologic locally advanced or metastatic tumour (lung cancer · renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination) · head and neck cancerFrance - RecruitingPHASE1
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
This study is testing a new drug, Ris-Rez, for people with advanced cancers. Researchers want to see if it's safe, how it works, and if it can help stop cancer growth, both alone and with other medicines.
For: NeoplasmsUnited States · Argentina · Canada - Active not recruitingPHASE1, PHASE2
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This study is testing different combinations of new drugs, including EOS-448, with or without standard treatments for advanced cancers like lung and head & neck cancer, and melanoma. Researchers want to see if these combinations are safe and effective.
For: Advanced Cancer · Lung Cancer · Head and Neck CancerUnited States · Belgium · France - Active not recruitingPHASE1
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
This study looks at a new treatment called remzistotug for advanced cancers that haven't responded to usual treatments. It's the first time it will be tested in people to check if it's safe and how it works in the body.
For: NeoplasmsUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)
This study looks at new ways to predict how well people with lung cancer might respond to certain treatments. It uses special tests on blood, lab-grown tumour models, and body scans to understand the cancer better and help doctors choose the best treatment.
For: Lung Cancer, Non-Small CellUnited Kingdom - RecruitingPHASE1, PHASE2
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
This study looks at a new drug, Mo-Rez, combined with other cancer treatments for advanced solid tumours – cancers that have spread. We want to see how safe and effective this combination is for people whose current treatments aren't working or who can't tolerate them.
For: Tumours, GynecologicalUnited States · Argentina · Australia - Active not recruitingPHASE2
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
This study is looking at new combinations of medicines for advanced lung cancer that hasn't been treated before. We want to see how safe these new treatments are and how well they work together. It's for people whose cancer shows high levels of a specific marker called PD-L1.
For: Lung Cancer, Non-Small CellUnited States · Argentina · Belgium - RecruitingPHASE2
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
This study is testing a new combination treatment for colon cancer before surgery. It combines a new drug, dostarlimab, with standard chemotherapy (CAPEOX) to see if it works better than chemotherapy alone for a specific type of colon cancer.
For: Neoplasms, ColonBelgium · Italy · Japan - Active not recruitingPHASE3
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
This study is looking at a new treatment called dostarlimab for advanced or recurring endometrial cancer that has a specific genetic feature (MMR deficient). It compares dostarlimab with standard chemotherapy to see which works better and is safer for patients.
For: Endometrial CancerAustralia · Canada · France - RecruitingPHASE3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
This study looks at a new drug, Dostarlimab, for adults with a certain type of head and neck cancer. It compares Dostarlimab to a dummy drug (placebo) after standard chemo and radiation, to see if it's safe and effective.
For: Neoplasms, Head and NeckUnited States · Argentina · Australia - Active not recruitingPHASE1
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
This study is testing a new drug called dostarlimab for people with advanced cancers that haven't responded to other treatments. It aims to find the safest and most effective dose, and see how well it works against different types of advanced solid tumours.
For: NeoplasmsUnited States · Brazil · Canada - RecruitingPHASE3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
This study looks at a new treatment called dostarlimab for certain types of colon cancer that haven't spread. It compares dostarlimab with standard treatments to see if it works better before and after surgery to help patients.
For: Colonic Neoplasms · Neoplasms, ColonUnited States · Argentina · Australia - Active not recruitingPHASE1
A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
This study is testing a new medicine, GSK3745417, alone or with another drug, dostarlimab, for people with advanced cancers. The aim is to see if it's safe, how well it's tolerated, find the right dose, and check its early effects against cancer.
For: NeoplasmsUnited States · Australia · Canada - RecruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
For: Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical NeoplasmsAustralia · Hong Kong · Japan - Active not recruitingPHASE2
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
This study looks at a new drug called dostarlimab for people with a specific type of early rectal cancer (dMMR/MSI-H) who haven't had other treatments. The aim is to see if dostarlimab alone can help avoid chemotherapy, radiation, and surgery.
For: Neoplasms, RectalUnited States · Canada · France - Active not recruitingPHASE3
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
This study looks at new ways to treat advanced or returning womb cancer. It compares a drug called dostarlimab, with or without another drug called niraparib, alongside standard chemotherapy, against chemotherapy plus a dummy drug, to see if these new treatments work better and are safe.
For: NeoplasmsUnited States · Belarus · Belgium - Active not recruitingPHASE3
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
This study is looking at a new combination of medicines, belrestotug and dostarlimab, for people with a certain type of lung cancer that hasn't been treated before. It compares this combination to a standard treatment (pembrolizumab) and a dummy drug (placebo).
For: Lung Cancer, Non-Small CellUnited States · Argentina · Belgium - Active not recruitingPHASE1
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
This study is testing new medicines for advanced cancers that have grown. It particularly looks at how safe these new drugs are and how well they work, both alone and with existing treatments. The research also wants to understand how the body uses these new drugs.
For: NeoplasmsUnited States · Canada · Japan